Waldenstrom macroglobulinemia (WM) is a type of blood cancer that begins in the white blood cells. It usually progresses very slowly, and patients without symptoms may not require treatment for months, years or potentially ever. WM is classified as a non-Hodgkin lymphoma (NHL) because it first occurs in the B-lymphocytes (B-cells).
According to the International Waldenstrom’s Macroglobulinemia Foundation (IWMF), less than 1,500 people in the United States are diagnosed with WM each year, making it an extremely rare type of cancer. It is most often diagnosed in individuals who are 65 years of age and above. It is also more common in men than in women.
There are many treatments available for WM, including chemotherapy, immunotherapy and targeted therapy. Recent research has made great strides in the treatment of the disease, and the median survival for patients has been improving with these newer treatments.
To learn more about the disease, navigate to "What is Waldenstrom macroglobulinemia?"